Marjoram for Hormonal Balance and Polycystic Ovary Syndrome (PCOS)

This is the most interesting page on marjoram, and it rests mainly on one small study. That sentence is the whole article in miniature, and we want it at the top rather than buried under enthusiasm.

In 2016, a research group in Jordan published a randomized, double-blind, placebo-controlled pilot trial in which 25 women with polycystic ovary syndrome drank sweet marjoram tea (Origanum majorana; 14 women) or a placebo tea (11 women) twice a day for a month. The authors concluded that the tea led to improved insulin sensitivity and a reduction in dehydroepiandrosterone sulfate (DHEA-S), an androgen made by the adrenal glands. The paper is Haj-Husein, Tukan and Alkazaleh, The effect of marjoram (Origanum majorana) tea on the hormonal profile of women with polycystic ovary syndrome: a randomised controlled pilot study, in the Journal of Human Nutrition and Dietetics.

That is a genuinely well-designed study of a cheap, safe, pleasant intervention in a condition where women are frequently offered very little. It is also a pilot: 25 participants, one month of exposure, blood markers rather than symptoms or outcomes, and — nearly a decade on — no published replication of marjoram tea alone; the one later trial in this condition, from 2025, used a marjoram and cinnamon blend. Both halves of that assessment are true at the same time, and this page tries to hold them together instead of picking whichever half makes a better headline.


Table of Contents

  1. What Polycystic Ovary Syndrome Actually Is
  2. The Trial: How It Was Built
  3. What It Reported
  4. What It Cannot Tell Us
  5. Insulin Sensitivity: Why This Is the Real Story
  6. DHEA-S and the Adrenal Side of Polycystic Ovary Syndrome
  7. Plausible Mechanisms
  8. The Spearmint Precedent
  9. Where Marjoram Sits Among Real Polycystic Ovary Syndrome Treatments
  10. Menstrual Pain and the Emmenagogue Tradition
  11. How Marjoram Tea Is Made and Taken
  12. Safety, Pregnancy and Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

What Polycystic Ovary Syndrome Actually Is

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, and it is badly named — the cysts are not really cysts, and plenty of women with the syndrome do not have them. What defines it is a cluster: irregular or absent ovulation, clinical or biochemical excess of androgens (acne, unwanted hair growth, scalp hair thinning, or raised androgen levels on a blood test), and often polycystic-appearing ovaries on ultrasound. Diagnosis conventionally requires two of the three, with other causes excluded.

The condition has now been renamed: a 2026 report describes the change to polyendocrine metabolic ovarian syndrome, after an international consensus process endorsed by 56 professional and patient organizations, because the ovaries hold numerous arrested follicles, not true cysts. It affects about 10% to 13% of women of reproductive age. The diagnostic criteria are unchanged: two of irregular cycles with ovulation problems, androgen excess, and raised anti-Müllerian hormone or multiple follicles on ultrasound in adults. This page keeps the older name, which is the one the trials below use.

Two engines drive most of it. The first is insulin resistance: the body's cells respond poorly to insulin, the pancreas compensates by producing more, and high circulating insulin drives the ovary to make more androgen while also suppressing the liver protein (sex hormone-binding globulin) that would otherwise keep androgens bound and inactive. Less binding protein means more free, biologically active testosterone from the same total. The second engine is a disturbed pituitary signalling pattern that further pushes ovarian androgen production.

Understanding the insulin engine is what makes the marjoram finding interesting rather than random. Insulin resistance is not a side effect of polycystic ovary syndrome (PCOS) — for many women it is upstream of the whole picture, which is why metformin, an insulin-sensitising drug, is a mainstay of treatment and why weight change, activity and diet quality have such disproportionate effects. Any intervention that plausibly improves insulin sensitivity is pulling on the right lever. Whether marjoram tea pulls hard enough to matter is exactly the open question.

The Trial: How It Was Built

Evidence tier: randomized clinical trial (pilot).

The design deserves credit, because a lot of herbal research does not bother with any of it.

Nothing about this is sloppy. It is a properly conducted small trial that its own authors labelled a pilot — that is, a study designed to find out whether a bigger study is worth running, not to answer the clinical question.

What It Reported

Two findings carried the paper.

1. Improved insulin sensitivity

The results were mixed, and the authors concluded that insulin sensitivity improved. Fasting insulin fell within the marjoram group by a mean of 1.9 µU/mL (P < 0.05), but that change was not significant against placebo (P = 0.08). HOMA-IR did not fall significantly within the marjoram group (P = 0.06), though its change was significant against placebo (P < 0.05). HOMA-IR is a calculated measure — derived from fasting glucose and fasting insulin — that estimates how efficiently insulin is working. It is a standard, practical way to assess insulin sensitivity outside a research laboratory, and it is also an indirect estimate rather than a direct measurement of glucose disposal.

2. Reduced DHEA-S

DHEA-S is an androgen produced by the adrenal cortex. It fell by a mean of 1.4 µmol/L in the marjoram group (P < 0.05), and the change against placebo sat exactly on the usual line of significance (P = 0.05). In polycystic ovary syndrome, roughly a quarter to a third of women have an adrenal contribution to their androgen excess on top of the ovarian one, and DHEA-S is the marker that captures it. A tea that moves it is doing something specific rather than generic.

What was not the headline

The findings the paper foregrounds are those two. The abstract lists follicle-stimulating hormone, luteinising hormone, progesterone, oestradiol and total testosterone among the measures taken and reports no result for them. It does not list free testosterone at all — the fraction driving acne and hair changes, and the androgen most directly tied to the symptoms women actually report.

What It Cannot Tell Us

Five limitations, each of which independently prevents this from being a settled result.

  1. Size. A pilot of 25 women split 14 and 11 can detect only large effects, and with each woman drinking only one tea it has less power than if she had served as her own control. The DHEA-S result sat exactly on the line of significance (P = 0.05). Small trials systematically overstate the effects they do find. This is one of the most reliable patterns in clinical research: when a small positive trial is followed by a large one, the effect usually shrinks, sometimes to nothing. Expecting the marjoram effect to be smaller than reported is the statistically literate default, not cynicism.
  2. Duration. One month. Polycystic ovary syndrome is a lifelong condition managed over years. A month tells you a marker can move; it says nothing about whether it stays moved, whether the body adapts, or whether anything clinically meaningful follows.
  3. Surrogate endpoints. The trial measured blood markers, not outcomes. It did not show restored ovulation, more regular periods, improved fertility, less acne or hair growth, weight change, or reduced long-term risk of type 2 diabetes. Those are what women with polycystic ovary syndrome actually want, and the study did not measure them. Surrogate markers moving in the right direction is encouraging; the history of medicine is full of surrogate markers that moved beautifully while patients got no better.
  4. No replication. This is the big one. A single positive pilot is a hypothesis. Nearly a decade later there is still no independent trial of marjoram tea alone in polycystic ovary syndrome. The closest is a 2025 randomized double-blind pilot in which 60 women were assigned a marjoram and cinnamon tea or a placebo tea twice daily for 3 months, and 36 finished. Follicle-stimulating hormone rose and anti-Müllerian hormone fell with the herbal tea, though anti-Müllerian hormone also fell with placebo; no major side effects were reported. As a blend it cannot be credited to marjoram alone. The PubMed search for marjoram and polycystic ovary syndrome is short enough that you can check this yourself in a minute, and we would encourage you to.
  5. Blinding of an aromatic tea. Marjoram has an unmistakable smell. However carefully the placebo was matched, some participants may have worked out which tea they had, and expectation influences self-reported outcomes far more than blood chemistry — which is, incidentally, a mild argument in favour of taking the biochemical findings more seriously than any subjective ones.

Insulin Sensitivity: Why This Is the Real Story

If any part of the marjoram finding turns out to be durable, this is the part that would matter most, so it is worth understanding why.

In polycystic ovary syndrome, high insulin is not just a metabolic nuisance sitting alongside the hormonal problem — it is often causing it. Insulin acts directly on ovarian theca cells to increase androgen output, and it suppresses hepatic production of sex hormone-binding globulin, which raises the free fraction of whatever testosterone is present. Lower the insulin and you pull on both threads at once: less ovarian drive, more binding capacity, less free androgen. That is the mechanism through which weight loss, exercise and metformin all produce hormonal improvements without ever touching a hormone.

It is also why the long game in polycystic ovary syndrome is metabolic. Women with polycystic ovary syndrome carry substantially elevated lifetime risk of type 2 diabetes, gestational diabetes and metabolic syndrome. Insulin sensitivity is not a laboratory abstraction; it is the variable that decides much of the next thirty years.

Which sets up the honest verdict. A cheap, safe tea that nudges insulin sensitivity would be a welcome addition to a metabolic strategy. But “addition” is the operative word. The interventions with large, replicated effects on insulin sensitivity in polycystic ovary syndrome are physical activity, dietary quality, sleep, modest weight loss where relevant, and metformin. Marjoram tea, on current evidence, is a plausible garnish on that plan. It is not one of the load-bearing elements, and treating it as one would be a real cost — because the load-bearing elements are the ones that actually change outcomes.

DHEA-S and the Adrenal Side of Polycystic Ovary Syndrome

DHEA-S is worth a section because it is the finding people skip past, and it is arguably the more novel one.

Androgen excess in polycystic ovary syndrome has two sources. The ovary is the main one. But a substantial minority of women also have an adrenal contribution, and DHEA-S — produced almost entirely by the adrenal cortex, circulating at high concentration with a long half-life — is the cleanest single marker of it. Because it is stable through the day, it is also one of the more reliable androgen measurements you can take, unlike testosterone, which fluctuates.

Clinically, adrenal-predominant androgen excess tends to respond less well to treatments aimed at the ovary. So an intervention that moves DHEA-S is targeting a real gap. What is unknown is how: nobody has shown whether marjoram affects adrenal steroid synthesis directly, acts through the pituitary signal that drives the adrenal cortex, alters the enzymes that interconvert androgens in peripheral tissue, or simply follows along behind the insulin change. Until somebody looks, the DHEA-S result is a real observation without a mechanism.

One safety fact. DHEA-S is also a diagnostic test: a markedly raised level is what doctors look to for congenital adrenal hyperplasia or an androgen-secreting tumour, not for polycystic ovary syndrome. That is why doctors check it, and a tea that may lower the number does nothing for either of those causes.

Plausible Mechanisms

Evidence tier: preliminary and speculative.

The trial did not investigate mechanism, so what follows is hypothesis. We are flagging it as such because this is exactly the point at which health writing usually starts asserting things.

The Spearmint Precedent

Evidence tier: randomized clinical trials, different plant.

Marjoram's polycystic ovary syndrome trial did not appear out of nowhere. It followed a small but real line of work on another mint-family tea.

Grant published Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial in Phytotherapy Research in 2010, following Akdoğan and colleagues' Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism in the same journal in 2007. Both reported that spearmint tea lowered androgen measures in women with androgen-excess conditions. The details bear on marjoram: Akdoğan's 21 women had no control group described and drank the tea for 5 days; free testosterone fell, but there was no significant fall in total testosterone or DHEA-S, the marker that moved in the marjoram trial. In Grant's 30-day trial of 42 women, free and total testosterone fell and women rated their own hair growth as improved, but the objective Ferriman-Gallwey hair score did not differ between groups (p = 0.12).

Two things follow. First, the marjoram trial was a reasonable hypothesis rather than a shot in the dark: a chemically related Lamiaceae infusion had already produced a signal. Second — and this is the sobering part — spearmint has been in this literature since 2007 and still has not accumulated the trial base to become a recommended treatment. Its results were also small, also short, and also thinly replicated. That is the realistic trajectory for a herbal tea finding: not disproof, but a long plateau of promise. Marjoram is roughly nine years behind spearmint on the same road.

Where Marjoram Sits Among Real Polycystic Ovary Syndrome Treatments

Placing it honestly is more respectful of your time than praising it.

That does not count against marjoram tea. It places it correctly: a pleasant, near-zero-risk addition to a plan whose real work is done elsewhere. Feeling engaged in managing one's own condition is a genuine and underrated benefit. When a tea takes the place of the treatments above, the loss is what those treatments have been shown to do.

Menstrual Pain and the Emmenagogue Tradition

Evidence tier: randomized clinical trial of a blend, plus traditional use.

Marjoram has a second, older hormonal reputation: as an emmenagogue, a plant used to bring on or regulate menstruation. This tradition is well attested and is the direct source of the pregnancy caution repeated throughout this site — a reputation for stimulating menstruation is the reason medicinal quantities are flagged in pregnancy. Note carefully what that means as evidence: the tradition supports the caution, not the efficacy. No controlled study has tested whether marjoram affects menstrual timing at all.

There is one relevant piece of human trial data, and it is topical rather than internal. Ou and colleagues published Pain relief assessment by aromatic essential oil massage on outpatients with primary dysmenorrhea: a randomized, double-blind clinical trial in the Journal of Obstetrics and Gynaecology Research in 2012. In that trial 48 women with painful periods (24 per group) massaged the lower abdomen daily with an unscented cream holding 3% essential oils (lavender, clary sage and marjoram, 2:1:1) or with a cream holding synthetic fragrance. Pain scores fell in both groups after one cycle (P < 0.001); the reported difference was the duration of pain, which fell from 2.4 to 1.8 days in the essential-oil group.

The value and the limitation are the same fact: it was a blend, and marjoram was one of three oils. Lavender has by far the largest independent trial base of the three, so it is the most likely primary contributor. A positive blend result cannot be divided among its components. What it does support is a low-risk, non-drug option for period pain — abdominal massage with a diluted aromatic cream — without licensing any claim about marjoram specifically.

How Marjoram Tea Is Made and Taken

There is no established therapeutic dose of marjoram for anything. Tea regimens have been tested in people in this trial, in randomized double-blind trials in Parkinson's disease (30 days, one of them once daily with 30 people on the tea and 25 on placebo tea) and in the 2025 marjoram and cinnamon trial. The regimen tested for this condition with marjoram alone is the Jordan trial's:

Safety, Pregnancy and Interactions

Marjoram tea is about as low-risk as a botanical intervention gets. The cautions that exist are real but narrow.

Key Research Papers

  1. Randomized clinical trial (pilot) — Haj-Husein I, Tukan S, Alkazaleh F. The effect of marjoram (Origanum majorana) tea on the hormonal profile of women with polycystic ovary syndrome: a randomised controlled pilot study. Journal of Human Nutrition and Dietetics, 2016;29(1):105-111. The study this entire page is about. — PubMed PMID: 25662759
  2. Review — Bina F, Rahimi R. Sweet Marjoram: A Review of Ethnopharmacology, Phytochemistry, and Biological Activities. Journal of Evidence-Based Complementary & Alternative Medicine, 2017;22(1):175-185. An overview of what else is known about O. majorana — PubMed PMID: 27231340
  3. Randomized clinical trial, related plant — Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytotherapy Research, 2010;24(2):186-188. The precedent that made the marjoram hypothesis reasonable. — PubMed PMID: 19585478
  4. Clinical trial, related plant — Akdoğan M, et al. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytotherapy Research, 2007;21(5):444-447. The earlier spearmint work. — PubMed PMID: 17310494
  5. Randomized clinical trial, marjoram-containing blend — Ou MC, et al. Pain relief assessment by aromatic essential oil massage on outpatients with primary dysmenorrhea: a randomized, double-blind clinical trial. Journal of Obstetrics and Gynaecology Research, 2012;38(5):817-822. Lavender, clary sage and marjoram in unscented cream for period pain. — PubMed PMID: 22435409
  6. Preliminary (in vitro) — Roby MHH, et al. Evaluation of antioxidant activity, total phenols and phenolic compounds in thyme (Thymus vulgaris L.), sage (Salvia officinalis L.), and marjoram (Origanum majorana L.) extracts. Industrial Crops and Products, 2013;43:827-831. Quantifies the rosmarinic-acid-rich fraction proposed as the active principle. — doi:10.1016/j.indcrop.2012.08.029
  7. Preliminary (in vitro) — Erenler R, et al. Isolation and identification of chemical constituents from Origanum majorana and investigation of antiproliferative and antioxidant activities. Journal of the Science of Food and Agriculture, 2016;96(3):822-836. Individual marjoram constituents and their activity. — PubMed PMID: 25721137
  8. Preliminary (chemistry) — Vera RR, Chane-Ming J. Chemical composition of the essential oil of marjoram (Origanum majorana L.) from Reunion Island. Food Chemistry, 1999;66(2):143-145. Why marjoram oil is not oregano oil. — doi:10.1016/S0308-8146(98)00018-1
  9. Report on the rename — Bahri-Khomami M, Hoeger KM, Huddleston H, Mahalingaiah S, Teede HJ, Dokras A. From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know. American Journal of Obstetrics and Gynecology, 2026;235(5):999-1002. — PubMed PMID: 42665241
  10. Randomized clinical trial, marjoram-containing blend — Majeed NG, et al. Safety and effectiveness of marjoram and cinnamon herbal tea supplementation in managing polycystic ovary syndrome: a pilot randomized, double-blind, controlled trial. Annals of Medicine and Surgery, 2025;87(12):8326-8333. — PubMed PMID: 41377384
  11. Randomized clinical trial (marjoram, other condition) — Chahra C, Anis H, Bissene D, Mejda S, Jihène M, Salma N, Manel N, Sana BA, Hedi K, Maha BF. The effect of Origanum majorana tea on motor and non-motor symptoms in patients with idiopathic Parkinson's disease: A randomized controlled pilot study. Parkinsonism & Related Disorders, 2021;91:23-27. — PubMed PMID: 34455218
  12. Randomized clinical trial (marjoram, other condition) — Chahra C, Sawssen M, Anis H, Salma N, Manel N, Sana BA, Maha BF. Effect of Origanum majorana tea on oxidative stress biomarkers in Parkinson's disease: a randomized placebo-controlled pilot study. Neuroscience, 2025;587:139-145. — PubMed PMID: 41052623
  13. Open topic search — the replication question, answerable in one minute: marjoram and PCOS, everything indexed
  14. Open topic search — the interventions with the real evidence base, for comparison: inositol in PCOS and metformin and insulin sensitivity in PCOS
  15. Open topic search — the adrenal androgen question: DHEA-S and adrenal androgen excess in PCOS

Back to Table of Contents

Back to Table of Contents

Connections


Safety and disclaimer. This article is educational and is not medical advice. Polycystic ovary syndrome is a medical diagnosis with real long-term metabolic and fertility consequences — marjoram tea is not a treatment for it, and the single pilot trial described here does not make it one. The emmenagogue tradition is the source of the caution about medicinal doses in pregnancy or when trying to conceive; its vitamin K and laboratory platelet effects are the concern with anticoagulants; an added glucose-lowering effect is the theoretical concern with diabetes medicines. Marjoram essential oil has no established internal dose.

Back to Table of Contents